Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose COVID vaccine

The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20.

October 5, 2021 5:31 PM
BSE, Cadila Healthcare ZyCoV-D, DCGIEarlier in August, in a filing to BSE, Cadila Healthcare had said that it plans to seek approval for the two dose regimen of the vaccine. It had also mentioned that the company plans to manufacture 10-12 crore doses of ZyCoV-D annually.

Drug firm Cadila Healthcare has received permission from the the Drug Controller General of India (DCGI) for conducting phase III trials for its two-dose COVID-19 vaccine ZyCoV-D.

The company has got the permission for conduct of phase III trials for two-dose Covid vaccine,” Cadila Healthcare said in a regulatory filing.

Earlier in August, in a filing to BSE, Cadila Healthcare had said that it plans to seek approval for the two dose regimen of the vaccine. It had also mentioned that the company plans to manufacture 10 to 12 crore doses of ZyCoV-D annually.

The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20, 2021.

Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close.

Cadila is learnt to have proposed ₹1,900 for ZyCoV-D three-dose jab.

Cadila’s ZyCov-D- the world’s first Plasmid DNA Vaccine for Covid-19 is the only vaccine today approved by the Drug Controller General of India (DCGI) for emergency use in children aged 12 years and above.

 

 

 

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Latest Healthcare News